Free Delivery Over $100
|
|
|||
|
||||
OverviewJapan has succeeded in many industries through its renowned production system. Competitive advantage, however, in the new economy is shifting from production to demand-based capabilities. One such new industry is pharmaceuticals, where Japan has been a resounding failure, both from public policy and corporate strategy perspectives. This is a detailed examination of how Japan has socially constructed its pharmaceutical industry, the economic and political bases of this construction and the consequences for corporate innovation and performance. Perhaps the starkest indication of this failure of Japanese public policy is the emergence of a new drug lag in that nation. Almost 90 percent of recent important new drugs are unavailable in Japan, despite their widespread diffusion throughout the rest of the world. Analysis of this drug lag confirms that it is not due to government discrimination against Western firms, but rather is only one of many consequences of failed Japanese industrial policies. The author presents an analysis of the nature, causes and consequences of the new drug lag in Japan. He contrasts the problem with the one experienced in the USA and looks at the powerful role played by domestic politics in shaping the pharmaceutical industry. The last chapters look at the various remedies available. Full Product DetailsAuthor: L. G. Thomas, IIIPublisher: Edward Elgar Publishing Ltd Imprint: Edward Elgar Publishing Ltd Weight: 0.489kg ISBN: 9781840645804ISBN 10: 1840645806 Pages: 232 Publication Date: 28 August 2001 Audience: College/higher education , Professional and scholarly , Undergraduate , Postgraduate, Research & Scholarly Format: Hardback Publisher's Status: Active Availability: Out of stock  The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available. Table of ContentsContents: Introduction 1. Nature of the New Drug Lag 2. Industrial Policy and Domestic Ecosystems 3. The Domestic Japanese Ecosystem for Pharmaceuticals 4. Pathologies of the Japanese Domestic Ecosystem 5. Evidence: Declining Prices and Life Cycle Sales in Japan 6. Evidence: Declining Registrations in Japan 7. Evidence: Declining Launches in Japan 8. Evidence: Inflated Domestic Market Share in Japan 9. Challenges to the Dual State in Japan 10. Trade Law and Remedies for Market Exclusion References IndexReviewsAuthor InformationL.G. Thomas, III, Professor and Area Coordinator of Organization and Management, Goizueta Business School, Emory University, US Tab Content 6Author Website:Countries AvailableAll regions |
||||
